Intravenous Immunoglobulin as a Therapeutic Option in Severe COVID-19 Patient: Case Report
Journal: International Journal of Science and Research (IJSR) (Vol.10, No. 3)Publication Date: 2021-03-05
Authors : Yulia Karolina Kurniawati;
Page : 308-311
Keywords : COVID-19; IVIg;
Abstract
Background: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent for the ongoing pandemic of coronavirus disease 2019 (COVID-19). Until now, no definite effective treatment has been identified. Case Report: This article reports a 41 year old male, diagnosed with Confirmed Pneumonia COVID-19 with hypertension, transaminitis and obesity. The patient received high-dose intravenous immunoglobulin (IVIg) therapy. Conclusion: Patient was treated by intravenous immunoglobulin (IVIg) showed satisfactory recovery. Based on observations, IVIg should be considered in deteriorating patients infected with COVID-19. However further investigations are needed to explain this further.
Other Latest Articles
- Ankylosing Spondylitis: Review and Current Treatments
- The Influence of Fund Management Company Characteristics on ETF Performance
- Biocompatibility Driven Paradigm, a Suggested Hard Tissue Replacements Classification
- Soybean by-Products in the Diet of Monogastrics in Sub-Saharan Africa: A Review
- How to Increase Your Cash Flow by Receiving God Aton?s Abundance
Last modified: 2021-06-26 18:42:03